Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00 at Needham & Company LLC

Trevi Therapeutics (NASDAQ:TRVI) had its price objective upped by Needham & Company LLC from $22.00 to $24.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also issued reports on the stock. Stifel Nicolaus raised their price target on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Leerink Partners increased their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, March 9th. D. Boral Capital restated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Monday, March 9th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.33.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $10.69 on Wednesday. Trevi Therapeutics has a fifty-two week low of $4.85 and a fifty-two week high of $14.39. The firm has a market capitalization of $1.37 billion, a PE ratio of -33.41 and a beta of 0.94. The stock’s 50-day simple moving average is $11.15 and its 200-day simple moving average is $10.93.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. Sell-side analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TRVI. Caitong International Asset Management Co. Ltd acquired a new stake in Trevi Therapeutics in the 4th quarter valued at $50,000. Seven Fleet Capital Management LP purchased a new stake in Trevi Therapeutics in the 4th quarter worth $89,000. Invesco Ltd. raised its position in Trevi Therapeutics by 3.3% during the fourth quarter. Invesco Ltd. now owns 498,926 shares of the company’s stock worth $6,247,000 after acquiring an additional 15,856 shares during the period. KVP Capital Advisors LP acquired a new position in Trevi Therapeutics during the fourth quarter worth $5,183,000. Finally, XTX Topco Ltd purchased a new position in Trevi Therapeutics during the fourth quarter valued at $1,049,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.